


## PHARMACEUTICAL 2019

## CymaBay Therapeutics Inc. Rank 151 of 371





## PHARMACEUTICAL 2019

## CymaBay Therapeutics Inc. Rank 151 of 371

The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 341% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is -105%, being 226% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	181,562
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,415
Liabilities, Non-Current	0
Other Assets	2,280
Other Compr. Net Income	-14
Other Expenses	0
Other Liabilities	1,914
Other Net Income	-43
Property and Equipment	2,905
Research and Development	58,124
Revenues	0
Selling, General and Administrative Expense	14,381

Output Variable	Value in 1000 USD
Assets	186,747
Liabilities	16,329
Expenses	72,505
Stockholders Equity	170,418
Net Income	-72,548
Comprehensive Net Income	-72,555
Economic Capital Ratio	-105%